Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
A phase 1/2 trial of Epcoritamab, Prednisone, Cyclophosphamide, Doxorubicin, Rituximab and Vincristine in chronic lymphocytic leukaemia, run by Genmab, active and no longer recruiting.
Overview
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome is a phase 1/2 interventional study registered as NCT04623541 by Genmab, with 194 participants enrolled, started 2020-11-25 and due to reach its primary completion in 2027-12. Interventions recorded: Epcoritamab, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, Venetoclax, Lenalidomide and Pirtobrutinib.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
Shares Prednisone, Vincristine, Rituximab, Cyclophosphamide and the tag pipeline.
- TrialTucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype
Shares Prednisone, Vincristine, Cyclophosphamide, Doxorubicin and the tag pipeline.
- TrialA Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)
Shares Prednisone, Rituximab, Cyclophosphamide, Doxorubicin and the tag pipeline.
- TrialA Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma
Shares Prednisone, Vincristine, Rituximab, Doxorubicin and the tag pipeline.
- TrialA Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Shares Prednisone, Rituximab, Cyclophosphamide, Doxorubicin and the tag pipeline.
- TrialA Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Shares Eli Lilly (incl. Loxo), Rituximab, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)
Shares Prednisone, Cyclophosphamide, Doxorubicin and the tag pipeline.
- TrialA Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Shares Eli Lilly (incl. Loxo), Rituximab, Chronic lymphocytic leukaemia and the tag pipeline.